3月27日上午,信达生物(01801.HK)股价大涨13.83%。 前一晚,信达生物公布2024年业绩,实现了Non-IFRS(非国际财务报告准则)计量下的利润及EBITDA(税息折旧及摊销前利润)转正。 2024年,公司Non-IFRS利润为3.32亿元,Non-IFRS EBITDA为4.12亿元,这是公司登陆港股上市以来,首次在这些指标上实现转正,比计划中提前一年实现该目标。 Non-...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.